We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
9.00 | 0.67% | 1,350.50 | 1,350.00 | 1,350.50 | 1,353.00 | 1,341.00 | 1,341.00 | 1,277,794 | 10:41:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.37 | 55.61B |
Date | Subject | Author | Discuss |
---|---|---|---|
26/5/2022 06:46 | Pfizer has said it will no longer make a profit from selling its patented medicines to 45 of the world's low-income countries. Pfizer said the plan includes 23 patented medicines and vaccines which treat infectious and rare inflammatory diseases and certain cancers. It said new medicines and vaccines will also be sold at cost. Pfizer said its vaccine and anti-viral treatment for coronavirus would be included in the plan. The firm has previously been criticised for making profits from its coronavirus-related vaccines. | tradermichael | |
23/5/2022 09:24 | You would think so Trader M. Also, how will being a non executive with a electricity distribution company help G.S.K. Also, as a shareholder of National Grid plc, I wonder how much time and interest will take his responsibilities to the non executive roll there. Brian3777 | brian3777 | |
19/5/2022 13:29 | One would have thought that Iain Mackay, Executive Director and Chief Financial Officer, who has been appointed as a Non-executive Director of National Grid plc, would have his work cut out handling GSK's financial affairs? | tradermichael | |
19/5/2022 11:53 | Unilever xd today. | alphorn | |
19/5/2022 11:50 | At least we aren't in Unilever. | patientcapital | |
19/5/2022 11:24 | - and a 4% drop in the DOW yesterday | tradermichael | |
19/5/2022 10:25 | Hence the mini sell off i guess. | ifthecapfits | |
16/5/2022 15:24 | Goes XD on Thursday. | patientcapital | |
16/5/2022 11:00 | SocGen raises GlaxoSmithKline price target to 2,275 (2,115) pence - 'buy' Nice one.Would gladly take 2275p for my GSK. | garycook | |
16/5/2022 09:59 | SocGen raises GlaxoSmithKline price target to 2,275 (2,115) pence - 'buy' Looks a bit "rich" to me.. | geckotheglorious | |
16/5/2022 07:17 | USD 1.22 = £1 | tradermichael | |
13/5/2022 07:10 | Looked like part of Hal's share incentive plan rather than a standard purchase | watfordhornet | |
13/5/2022 06:36 | Biggish director buy yesterday | netcurtains | |
13/5/2022 01:19 | TM,Think your Broker got their facts wrong,by getting confused with the GSK name change GLAXOSMITHKLINE ORD GBP0.25 Event Type Name Change Description Name Change Old name: GlaxoSmithKline plc New name: GSK plc Expected effective date: Mid-May 2022 Please be informed that GlaxoSmithKline plc will change its name to GSK plc. The change is expected to become effective around the middle of May 2022. No action is required from shareholders in relation to the name change. | garycook | |
12/5/2022 08:33 | Yes, with xdiv next week and all ... ;0) | tradermichael | |
12/5/2022 08:30 | Good time to add gla | charlie9038 | |
11/5/2022 11:56 | 27 July 2022 Announcement of Q2 2022 results 2 November 2022 Announcement of Q3 2022 results 1 February 2023 Announcement of Q4 2022 results | waldron | |
11/5/2022 11:53 | Gsk is heavenly discounted at this price soon we will see a drastic race between funds to get in on the action 20 pounds herd we come im buying big time | jretlaw | |
09/5/2022 13:40 | Correct, thanks | abdullla | |
09/5/2022 11:20 | Further to my message ref. 29673, I have had an update from my broker who now states that the demerger will be complete by mid July 2022 (as most of us know). | tradermichael | |
07/5/2022 11:39 | Good point TM, although .... this isn't really a float in the traditional sense. I am a bit confused about how it will work exactly, but as I understanding ~1/3 of Haleon (the name is growing on me) belongs to Pfizer and ~2/3 to GSK and the shares will be apportioned accordingly and in GSK's case, 80% of the 2/3 will be passed on to (us) shareholders. I presume there are no new shares being issued/funds raised, or perhaps there will be? I know the Execs have been courting sovereign wealth funds etc, so I guess there may be an element of investment required at IPO, or is it more to do with ensuring a health demand for shares post IPO for those current shareholders who don't want to hold Haleon stock? | spyder | |
07/5/2022 07:32 | The Nasdaq is now in a “bear market” after falling 22pc since the start of the year. April was its worst month since the 2008 financial crisis. The broader S&P 500 shed almost 4pc as the sell-off spread to other stocks, erasing about $1.3 trillion of market value. TRADITIONALLY, THIS IS NOT A GOOD TIME TO FLOAT A NEW COMPANY! | tradermichael | |
07/5/2022 07:32 | From GSK FAQs page on their website:"2. When is the demerger taking place?The demerger and listing of Haleon is expected to take place in July 2022." | patientcapital | |
07/5/2022 07:20 | That's what I thought so I checked twice with AJ Bell and they gave out the same dates. I still believe July 2022 is correct. I have asked my broker to double check with Glaxo. | tradermichael |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions